Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring of minimal residual disease in acute myeloid leukemia.

Cancer - 1 Jan 2008

Kern Wolfgang, Haferlach Claudia, Haferlach Torsten, Schnittger Susanne

Abstract excerpt

Two highly sensitive methods, multiparameter flow cytometry (MFC) and real-time quantitative PCR (RQ-PCR), are increasingly used to monitor minimal residual disease (MRD) and to guide risk-adapted management in acute myeloid leukemia (AML). An independent prognostic impact has been demonstrated for MRD levels obtained by both methods. MFC has been found particularly useful for assessment of early clearance of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Flow Cytometry
Share to Immunophenotyping

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Monitoring, Physiologic

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to Recurrence

Source

Identifiers

PMID: 18000811
DOI: 10.1002/cncr.23128

Genes

FLT3
NPM1
PML
RARA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring of minimal residual disease in acute myeloid leukemia.PMID 18000811Read ↗

Minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemiaSemantic proximity Read ↗

Detection of minimal residual disease in acute myelogenous leukemia.Semantic proximity Read ↗

MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.Semantic proximity Read ↗

Monitoring minimal residual disease in AML: the right time for real time.Semantic proximity Read ↗

Current strategies for detection and approach to measurable residual disease in acute myeloid leukemia.Semantic proximity Read ↗

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.Semantic proximity Read ↗

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?Semantic proximity Read ↗

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.Semantic proximity Read ↗

Minimal residual disease in acute myeloid leukemia: coming of age.Semantic proximity Read ↗

The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia.Semantic proximity Read ↗

Molecular Minimal Residual Disease Monitoring in Acute Myeloid Leukemia: Challenges and Future Directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.